Eli Lilly and Company (LLYCL)
Summary
LLYCL Chart
Eli Lilly and Company (LLY) Q1 2025 Earnings Call Transcript
Eli Lilly and Company (NYSE:LLY ) Q1 2025 Results Conference Call May 1, 2025 10:00 AM ET Company Participants Mike Czapar - Senior Vice President of Investor Relations Dave Ricks - Chair and CEO Lucas Montarce - Chief Financial Officer Dan Skovronsky - Chief Scientific Officer & President of Lilly Immunology Patrik Jonsson - President of Lilly Cardiometabolic Health & Lilly USA Anne White - President of Lilly Neuroscience Ilya Yuffa - President of Lilly International Jake Van Naarden - President of Lilly Oncology Marc Kemen - Investor Relations Wes Taul - Investor Relations Wai Wong - Investor Relations Conference Call Participants Asad Haider - Goldman Sachs Geoff Meacham - Citibank Chris Schott - JPMorgan Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo Alex Hammond - Wolfe Seamus Fernandez - Guggenheim Tim Anderson - Bank of America Evan Seigerman - BMO Capital Markets James Shin - Deutsche Bank Umer Raffat - Evercore Steve Scala - TD Cowen Courtney Breen - Bernstein David Risinger - Leerink Partners Kerry Holford - Berenberg Akash Tewari - Jefferies Trung Huynh - UBS Carter Gould - Cantor Rajesh Kumar - HSBC Kripa Devarakonda - Truist Securities Operator Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
LLY's Q1 Earnings Miss, Mounjaro & Zepbound Drive Sales, Stock Down
Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat estimates.
Jobless Claims Higher; Q1 Earnings from LLY, MCD & More
Last week, 241K Americans filed for unemployment on Initial Jobless Claims, with Continuing Claims touching 1.9 million.
Eli Lilly and Company Dividends
 LLY In 1 weeks Estimated | Quarterly | $1.5 Per Share |
| LLY 2 months ago Paid | Quarterly | $1.5 Per Share |
| LLY 5 months ago Paid | Quarterly | $1.3 Per Share |
| LLY 8 months ago Paid | Quarterly | $1.3 Per Share |
| LLY 11 months ago Paid | Quarterly | $1.3 Per Share |
| LLY 14 Feb 2024 Paid | Quarterly | $1.3 Per Share |
Eli Lilly and Company Earnings
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 6 Feb 2025 Date | | 5.07 Cons. EPS | 5.32 EPS |
| 4 Feb 2025 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | 1.47 Cons. EPS | 1.18 EPS |
| 8 Aug 2024 Date | | 2.6 Cons. EPS | 3.92 EPS |
| LLY In 1 weeks Estimated | Quarterly | $1.5 Per Share |
| LLY 2 months ago Paid | Quarterly | $1.5 Per Share |
| LLY 5 months ago Paid | Quarterly | $1.3 Per Share |
| LLY 8 months ago Paid | Quarterly | $1.3 Per Share |
| LLY 11 months ago Paid | Quarterly | $1.3 Per Share |
| LLY 14 Feb 2024 Paid | Quarterly | $1.3 Per Share |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 6 Feb 2025 Date | | 5.07 Cons. EPS | 5.32 EPS |
| 4 Feb 2025 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | 1.47 Cons. EPS | 1.18 EPS |
| 8 Aug 2024 Date | | 2.6 Cons. EPS | 3.92 EPS |
Eli Lilly and Company (LLYCL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Eli Lilly and Company ever had a stock split?
Eli Lilly and Company Profile
| Drug Manufacturers—General Industry | Healthcare Sector | Mr. David A. Ricks CEO | XSGO Exchange | US5324571083 ISIN |
| United States Country | 43,000 Employees | 14 Feb 2025 Last Dividend | 16 Oct 1997 Last Split | 13 Jan 1978 IPO Date |
Overview
Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.
Products and Services
- Diabetes Care
Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.
- Oncology
Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.
- Immunology
Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
- Digestive Diseases
Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.
- Neurological Disorders
Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.
- Other Therapeutic Areas
The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.
Contact Information
